Close Menu

We Can’t Rely on Just One Company To Distribute COVID Vaccines

Dean Emeritus Admiral James Stavridis explores the challenges the U.S. faces in manufacturing, distributing, and administering a COVID-19 vaccine, via an op-ed for Fortune.

With cases of COVID-19 surging across the country, there has been incredible urgency for a safe and effective vaccine. But there are sobering messages from public health officials and vaccine company executives in recent days that the vaccine likely won’t be available to a majority of the U.S. population until well into 2021.

The approval of a vaccine, however, will only be the first step toward restoring the health and security of our nation. There is an important distinction between the creation of a vaccine designed to prevent the spread of COVID-19 and a successful process of manufacturing, distribution, and administration. 

Read More

Categories